1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Stem Cell Therapy for Neurological Disorders Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Stem Cell Therapy for Neurological Disorders Market, by Cell Type
8.1.1. Mesenchymal Stem Cells (MSCs)
8.1.1.1. Market Revenue and Forecast
8.1.2. Neural Stem Cells (NSCs)
8.1.2.1. Market Revenue and Forecast
8.1.3. Induced Pluripotent Stem Cells (iPSCs)
8.1.3.1. Market Revenue and Forecast
8.1.4. Hematopoietic Stem Cells (HSCs)
8.1.4.1. Market Revenue and Forecast
8.1.5. Embryonic Stem Cells (ESCs)
8.1.5.1. Market Revenue and Forecast
9.1. Stem Cell Therapy for Neurological Disorders Market, by Disorder Type
9.1.1. Alzheimer’s Disease
9.1.1.1. Market Revenue and Forecast
9.1.2. Parkinson’s Disease
9.1.2.1. Market Revenue and Forecast
9.1.3. Amyotrophic Lateral Sclerosis (ALS)
9.1.3.1. Market Revenue and Forecast
9.1.4. Multiple Sclerosis
9.1.4.1. Market Revenue and Forecast
9.1.5. Stroke
9.1.5.1. Market Revenue and Forecast
10.1. Stem Cell Therapy for Neurological Disorders Market, by Therapy Type
10.1.1. Autologous Stem Cell Therapy
10.1.1.1. Market Revenue and Forecast
10.1.2. Allogeneic Stem Cell Therapy
10.1.2.1. Market Revenue and Forecast
11.1. Stem Cell Therapy for Neurological Disorders Market, by End-Use
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Specialty Neurology Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Research Institutes & Academic Centers
11.1.3.1. Market Revenue and Forecast
11.1.4. Regenerative Medicine Centers
11.1.4.1. Market Revenue and Forecast
12.1. Stem Cell Therapy for Neurological Disorders Market, by Route of Administration
12.1.1. Intrathecal
12.1.1.1. Market Revenue and Forecast
12.1.2. Intravenous
12.1.2.1. Market Revenue and Forecast
12.1.3. Intracerebral
12.1.3.1. Market Revenue and Forecast
12.1.4. Others
12.1.4.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Cell Type
13.1.2. Market Revenue and Forecast, by Disorder Type
13.1.3. Market Revenue and Forecast, by Therapy Type
13.1.4. Market Revenue and Forecast, by End-Use
13.1.5. Market Revenue and Forecast, by Route of Administration
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Cell Type
13.1.6.2. Market Revenue and Forecast, by Disorder Type
13.1.6.3. Market Revenue and Forecast, by Therapy Type
13.1.6.4. Market Revenue and Forecast, by End-Use
13.1.6.5. Market Revenue and Forecast, by Route of Administration
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Cell Type
13.1.7.2. Market Revenue and Forecast, by Disorder Type
13.1.7.3. Market Revenue and Forecast, by Therapy Type
13.1.7.4. Market Revenue and Forecast, by End-Use
13.1.7.5. Market Revenue and Forecast, by Route of Administration
13.2. Europe
13.2.1. Market Revenue and Forecast, by Cell Type
13.2.2. Market Revenue and Forecast, by Disorder Type
13.2.3. Market Revenue and Forecast, by Therapy Type
13.2.4. Market Revenue and Forecast, by End-Use
13.2.5. Market Revenue and Forecast, by Route of Administration
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Cell Type
13.2.6.2. Market Revenue and Forecast, by Disorder Type
13.2.6.3. Market Revenue and Forecast, by Therapy Type
13.2.7. Market Revenue and Forecast, by End-Use
13.2.8. Market Revenue and Forecast, by Route of Administration
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Cell Type
13.2.9.2. Market Revenue and Forecast, by Disorder Type
13.2.9.3. Market Revenue and Forecast, by Therapy Type
13.2.10. Market Revenue and Forecast, by End-Use
13.2.11. Market Revenue and Forecast, by Route of Administration
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Cell Type
13.2.12.2. Market Revenue and Forecast, by Disorder Type
13.2.12.3. Market Revenue and Forecast, by Therapy Type
13.2.12.4. Market Revenue and Forecast, by End-Use
13.2.13. Market Revenue and Forecast, by Route of Administration
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Cell Type
13.2.14.2. Market Revenue and Forecast, by Disorder Type
13.2.14.3. Market Revenue and Forecast, by Therapy Type
13.2.14.4. Market Revenue and Forecast, by End-Use
13.2.15. Market Revenue and Forecast, by Route of Administration
13.3. APAC
13.3.1. Market Revenue and Forecast, by Cell Type
13.3.2. Market Revenue and Forecast, by Disorder Type
13.3.3. Market Revenue and Forecast, by Therapy Type
13.3.4. Market Revenue and Forecast, by End-Use
13.3.5. Market Revenue and Forecast, by Route of Administration
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Cell Type
13.3.6.2. Market Revenue and Forecast, by Disorder Type
13.3.6.3. Market Revenue and Forecast, by Therapy Type
13.3.6.4. Market Revenue and Forecast, by End-Use
13.3.7. Market Revenue and Forecast, by Route of Administration
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Cell Type
13.3.8.2. Market Revenue and Forecast, by Disorder Type
13.3.8.3. Market Revenue and Forecast, by Therapy Type
13.3.8.4. Market Revenue and Forecast, by End-Use
13.3.9. Market Revenue and Forecast, by Route of Administration
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Cell Type
13.3.10.2. Market Revenue and Forecast, by Disorder Type
13.3.10.3. Market Revenue and Forecast, by Therapy Type
13.3.10.4. Market Revenue and Forecast, by End-Use
13.3.10.5. Market Revenue and Forecast, by Route of Administration
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Cell Type
13.3.11.2. Market Revenue and Forecast, by Disorder Type
13.3.11.3. Market Revenue and Forecast, by Therapy Type
13.3.11.4. Market Revenue and Forecast, by End-Use
13.3.11.5. Market Revenue and Forecast, by Route of Administration
13.4. MEA
13.4.1. Market Revenue and Forecast, by Cell Type
13.4.2. Market Revenue and Forecast, by Disorder Type
13.4.3. Market Revenue and Forecast, by Therapy Type
13.4.4. Market Revenue and Forecast, by End-Use
13.4.5. Market Revenue and Forecast, by Route of Administration
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Cell Type
13.4.6.2. Market Revenue and Forecast, by Disorder Type
13.4.6.3. Market Revenue and Forecast, by Therapy Type
13.4.6.4. Market Revenue and Forecast, by End-Use
13.4.7. Market Revenue and Forecast, by Route of Administration
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Cell Type
13.4.8.2. Market Revenue and Forecast, by Disorder Type
13.4.8.3. Market Revenue and Forecast, by Therapy Type
13.4.8.4. Market Revenue and Forecast, by End-Use
13.4.9. Market Revenue and Forecast, by Route of Administration
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Cell Type
13.4.10.2. Market Revenue and Forecast, by Disorder Type
13.4.10.3. Market Revenue and Forecast, by Therapy Type
13.4.10.4. Market Revenue and Forecast, by End-Use
13.4.10.5. Market Revenue and Forecast, by Route of Administration
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Cell Type
13.4.11.2. Market Revenue and Forecast, by Disorder Type
13.4.11.3. Market Revenue and Forecast, by Therapy Type
13.4.11.4. Market Revenue and Forecast, by End-Use
13.4.11.5. Market Revenue and Forecast, by Route of Administration
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Cell Type
13.5.2. Market Revenue and Forecast, by Disorder Type
13.5.3. Market Revenue and Forecast, by Therapy Type
13.5.4. Market Revenue and Forecast, by End-Use
13.5.5. Market Revenue and Forecast, by Route of Administration
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Cell Type
13.5.6.2. Market Revenue and Forecast, by Disorder Type
13.5.6.3. Market Revenue and Forecast, by Therapy Type
13.5.6.4. Market Revenue and Forecast, by End-Use
13.5.7. Market Revenue and Forecast, by Route of Administration
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Cell Type
13.5.8.2. Market Revenue and Forecast, by Disorder Type
13.5.8.3. Market Revenue and Forecast, by Therapy Type
13.5.8.4. Market Revenue and Forecast, by End-Use
13.5.8.5. Market Revenue and Forecast, by Route of Administration
14.1. BrainStorm Cell Therapeutics
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Mesoblast
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. ReNeuron Group
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Neuroplas
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Stempeutics Research
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. CorestemChemon
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Medipost
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Anterogen
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Pluri
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Aspen Neuroscience
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
